Paul Anthony Williams Sells 3,000 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Up 0.1%

EBS stock opened at $8.29 on Friday. The firm’s fifty day simple moving average is $8.36 and its 200-day simple moving average is $9.64. The company has a market capitalization of $427.47 million, a P/E ratio of -29.59 and a beta of 2.34. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. Emergent Biosolutions Inc. has a 12 month low of $5.61 and a 12 month high of $14.06.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. The firm had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Institutional Trading of Emergent Biosolutions

Several hedge funds have recently modified their holdings of the stock. Palumbo Wealth Management LLC raised its position in shares of Emergent Biosolutions by 143.0% during the 4th quarter. Palumbo Wealth Management LLC now owns 117,121 shares of the biopharmaceutical company’s stock worth $1,448,000 after acquiring an additional 68,925 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Emergent Biosolutions in the third quarter valued at approximately $713,000. American Century Companies Inc. increased its stake in Emergent Biosolutions by 3.9% in the third quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock valued at $21,013,000 after purchasing an additional 90,216 shares during the last quarter. Ritholtz Wealth Management purchased a new position in Emergent Biosolutions in the fourth quarter valued at approximately $1,346,000. Finally, Evolve Private Wealth LLC purchased a new position in Emergent Biosolutions in the first quarter valued at approximately $546,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings lowered Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright decreased their target price on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Finally, Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.